Home » Stocks » PLXP

PLx Pharma Inc. (PLXP)

Stock Price: $7.10 USD -1.05 (-12.88%)
Updated Mar 8, 2021 3:59 PM EST - Market closed
Market Cap 113.38M
Revenue (ttm) 54,323
Net Income (ttm) -10.77M
Shares Out 9.16M
EPS (ttm) -1.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $7.10
Previous Close $8.15
Change ($) -1.05
Change (%) -12.88%
Day's Open 8.29
Day's Range 7.06 - 8.23
Day's Volume 365,057
52-Week Range 1.80 - 10.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

SPARTA, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and ...

GlobeNewsWire - 5 days ago

SPARTA, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and ...

GlobeNewsWire - 6 days ago

SPARTA, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and ...

Benzinga - 1 week ago

PLx Pharma Inc (NASDAQ: PLXP) shares were trading higher Monday after the company announced that the U.S. Food and Drug Administration approved a supplemental new drug application for its lead...

GlobeNewsWire - 1 week ago

-- VAZALORE is the first ever liquid-filled aspirin capsule with an innovative delivery platform indicated as a pain reliever, fever reducer and for aspirin therapy in vascular indications –

Seeking Alpha - 3 months ago

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

--Announces $18 million private placement-- --Submitted sNDAs for VAZALORE 325 mg and 81 mg doses to FDA end of October--

GlobeNewsWire - 3 months ago

-- FDA sets estimated completion review date for the end of February 2021 -- -- Targeting launch of VAZALORE for third quarter 2021 –

GlobeNewsWire - 3 months ago

SPARTA, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-vali...

GlobeNewsWire - 4 months ago

SPARTA, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-vali...

GlobeNewsWire - 5 months ago

SPARTA, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-v...

Benzinga - 6 months ago

OConnor Rita M filed a Form 4 with the SEC on Wednesday, September 2. The insider bought 4,500 shares of PLx Pharma Inc (NASDAQ:PLXP) at $3.74 on Tuesday, Sep 01, and bought 2,120 shares at $3...

Seeking Alpha - 6 months ago

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

--Bioequivalence study of VAZALORE 325 mg on track with top-line data demonstrating bioequivalence to immediate release aspirin-- --Shifting the date of sNDA filings for VAZALORE 325 mg and 8...

GlobeNewsWire - 7 months ago

SPARTA, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-va...

GlobeNewsWire - 9 months ago

SPARTA, N.J., May 18, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clin...

Seeking Alpha - 9 months ago

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

-- Company to begin bioequivalence study of VAZALORE 325 mg dose ---- sNDA submissions expected by year-end -- SPARTA, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (...

Seeking Alpha - 11 months ago

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

-- PLx Aligning with the FDA on Data Requirements for VAZALORE  -- FDA Approves Labeling for 325 mg --  -- Expect to Launch VAZALORE in late 2020 -- SPARTA, N.J., Jan. 06, 2020 (GLOBE NEW...

Seeking Alpha - 1 year ago

PLx Pharma, Inc. (PLXP) CEO Natasha Giordano on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

VAZALORE’S novel mechanism of action with an improved GI safety profile also delivers fast, reliable absorption and predictable antiplatelet effect establishing bioequivalence with regular asp...

GlobeNewsWire - 1 year ago

SPARTA, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its cli...

Seeking Alpha - 1 year ago

PLx Pharma, Inc. (PLXP) CEO Natasha Giordano on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

PLx Pharma (PLXP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

PLx Pharma's (PLXP) CEO Natasha Giordano on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

PLx Pharma (PLXP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About PLXP

PLx Pharma, a late-stage specialty pharmaceutical company, focuses on developing the PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce novel gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention and treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
2002
Stock Exchange
NASDAQ
Ticker Symbol
PLXP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for PLx Pharma stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 69.01% from the latest price.

Price Target
$12.00
(69.01% upside)
Analyst Consensus: Buy